GSK-2018682

DB11987InvestigationalSmall molecule

GSK2018682 has been investigated for the treatment of Multiple Sclerosis, Relapsing-Remitting.

Chemical structure of GSK-2018682
Formula / weight
C22H21ClN4O4 · 440.88 g/mol (avg)
Code names
GSK2018682

Resolves to

Compound
UNIINJL503AIJACAS1034688-30-6PubChem24988201
Structure
InChIKeyNFIGDBFIDKDNIG-UHFFFAOYSA-NSMILESCC(C)OC1=C(Cl)C=C(C=N1)C1=NC(=NO1)C1=C2C=CN(CCCC(O)=O)C2=CC=C1
Targets
P21453S1PR1

What you can answer from here — as of January 29, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
2Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1+ReferenceStructured and connected to the statements they support
Sign in

Which drugs share a target with GSK-2018682, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In